Company: OCEA
Filing Date: 2025-01-13
Form Type: 10-Q
Source: 0001493152-25-001880
Chunk: 2

Company: Ocean Biomedical, Inc.
Filing Date: 2025-01-13
Form: 10-Q
Item: Item 1
Chunk 2
---
-  
     (686)
  
    Transaction costs 
     (77) 
     -  
     (77) 
     (8,732)
  
    Loss on extinguishment of debt 
     -  
     (224) 
     -  
     (15,080)
  
    Loss on exchange of notes 
     (1,899) 
     -  
     (1,899) 
     - 
  
    Interest expense, including amortization of debt issuance costs 
     (461) 
     (293) 
     (1,613) 
     (1,262)
  
    Net loss attributable to equity interest in Virion 
     (484) 
     -  
     (3,302) 
     - 
  
    Change in fair value of Virion contribution liability 
     (180) 
     -  
     240  
     - 
  
    Fair value of stock obligations 
     -  
     -  
     (47) 
     - 
  
    Other 
     -  
     (3) 
     -  
     (6)
  
    Total other income (expense) 
     (4,760) 
     (11,432) 
     (7,718) 
     (86,736)
  
    NET LOSS 
    $(5,528) 
    $(14,087) 
    $(9,763) 
    $(97,610)
  
    Weighted average shares outstanding, basic and diluted 
     27,487,283  
     26,605,147  
     27,446,868  
     25,980,292 
  
    Net loss per share, basic and diluted 
    $(0.20) 
    $(0.53) 
    $(0.36) 
    $(3.76)

See
accompanying notes to the unaudited condensed consolidated financial statements,

5

OCEAN
BIOMEDICAL, INC.

Condensed
Consolidated Statements of Stockholders’ Deficit

(in
thousands)

(unaudited)

For
the Three Months Ended September 30, 2024

    Shares  
    Amount  
    Capital  
    Deficit  
    Deficit 

    Common